PDA Announces Diverse 2019 Board of Directors 14 December, 2018

Bethesda, Md. – The Parenteral Drug Association (PDA) today announced the results of its Board of Directors Election for the term beginning January 1, 2019. In the fall of 2018, PDA’s 10,500 members had an opportunity to participate in the election of new directors.

The following candidates have been elected/appointed as Directors to the PDA Board of Directors for three-year terms starting Jan. 1, 2019:

• Michael Blackton, Adaptimmune
• Bettine Boltres, West Pharmaceutical Services*
• Stephan Krause, AstraZeneca Biologics
• Anil Sawant, Merck & Co.
• Melissa Seymour, Biogen

“I want congratulate the new Directors and thank the many members who took the time to vote.” said Richard Johnson, PDA President & CEO. “We had a high number of members vote in this year’s election, and I hope to see even more members participate in the future.

“PDA’s Board of Directors is one of the most diverse in the pharmaceutical industry, and it is the participation of our members in selecting the Directors that ensures this.”

PDA thanks outgoing Directors Susan Schniepp and Stephan Roenninger for their many years of service to PDA.

*Filling remainder of 2-year term of board member who resigned